Autologous Enriched T Cells Retrovirally Transduced To Express Two Chimeric Antigen Receptors Targeting Cd19 And Cd22

4 trials 2 recruiting Orphan designation

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

1 Completed trials

1 Sponsors

2 Countries

Phase II

Phase I/II

Phase I (Other)

Phase II: 2 Phase I/II: 1 Phase I (Other): 1

Indications tested

Non-Hodgkin's lymphoma 1 Systemic lupus erythematosus 1

Sponsors using this IMP

Autolus Limited 4

All trials

4 total

A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY TO DETERMINE THE SAFETY AND EFFICACY OF OBECABTAGENE AUTOLEUCEL (OBE-CEL) IN PARTICIPANTS WITH SEVE… Pending

2024-519941-32-00 Phase II 1 country Autolus Limited
Long-term follow-up of patients previously treated with autologous T cells genetically modified with viral vectors. Recruiting

2024-511684-28-00 Phase II 1 country Autolus Limited
A Single-Arm, Open-Label, Multicenter, Phase 1b/2 Study Evaluating the Safety and Efficacy of AUTO1 (obecabtagene autoleucel [obe-cel]) in P… Recruiting

2023-506307-26-00 Phase I (Other) 1 country Autolus Limited
An Open-Label, Multi-Centre, Phase Ib/II Study Evaluating the Safety and Efficacy of AUTO1, a CAR T Cell Treatment Targeting CD19, in Adult … Ended

2024-512903-38-00 Phase I/II 1 country Autolus Limited

Showing 1–4 of 4 trials

← All drugs A–Z